# ARA-290

> Erythropoietin-derived peptide researched for neuropathy and tissue repair.

Source: https://peptides.cafe/peptide/ara-290
Category: Neuropathic · Immune Modulation
Tag: Neuropathic pain · Immune

## Mechanism
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.

## Research areas
- Small-fiber neuropathy and sarcoidosis
- Diabetic neuropathy
- Ischemia-reperfusion injury
- Autoimmune modulation

## Common research protocols
- Subcutaneous research: Daily or twice-weekly subcutaneous dosing in neuropathy trials.

## Study summaries
- "ARA-290 in sarcoidosis-associated small-fiber neuropathy" — Neurology (2018): Improved pain scores and corneal nerve fiber density in sarcoidosis patients.
- "ARA-290 tissue protective effects" — British Journal of Pharmacology (2015): Reviewed non-hematopoietic protective mechanisms via the innate repair receptor.

## Considerations
- Investigational; not FDA-approved.
- Does not raise hematocrit like full EPO molecule.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.